

Friday 1st Aug 2025



Today's issue of *PD*

Pharmacy Daily today features two pages of news, plus full pages from:

- Glucojel
- Nova Pharmaceuticals

Attract customers

GLUCOJEL jellybeans can help reel more customers into your pharmacy.

Learn more about a discount offer on page three.

Treat skin conditions

NOVA Pharmaceuticals has a range of topical treatments for skin conditions, including anti-fungal Trimacorte, containing clotrimazole and hydrocortisone.

Also available is Dermacorte, containing hydrocortisone, for itching and inflammation.

See more on page four.

PSA25 Excellence Awards announced

THE winners of the highly anticipated 2025 PSA Symbion Excellence Awards were announced this morning at PSA25 in Sydney.

Jaimee Anderson of Katherine, NT, was named PSA Symbion Pharmacist of the Year, recognised for her exceptional leadership, innovation, and "unwavering commitment to the health and wellbeing of the Katherine community".

Working initially in one of Katherine's two pharmacies, Anderson has built a reputation for delivering high-quality, patient-centred care to both urban and remote populations.

She played a key role in the rollout of the NT's pharmacy-based vaccination services, and then became involved in primary healthcare teams working with First Nations people.

Identifying a critical gap in diabetes care, she became a credentialed diabetes educator (CDE), and now serves as the



pharmacist CDE at Wurli Wurlinjang Health Service, providing culturally safe, trauma-informed care to First Nations clients.

PSA National President Assoc Prof Fei Sim congratulated Anderson, and said: "Jaimee's work is a shining example of what pharmacists can achieve when they lead with heart, knowledge, and a deep connection to their community."

"Her impact in Katherine and beyond is truly inspiring.

"Jaimee's story reflects the very best of our profession - this recognition is very much deserved," Prof Fei Sim added.

Victorian pharmacist Dr Kate Wang was awarded 2025 PSA Symbion Early Career Pharmacist of the Year, recognised particularly for her work in improving quality use of medicines and medicine safety in aged care.

A senior lecturer in pharmacy at RMIT, Dr Wang is passionate about educating future pharmacists and expanding the profession's scope of practice.

Finally, Perth pharmacist Emeritus Professor Jeff David Hughes was recognised with the 2025 PSA Symbion Lifetime Achievement Award, acknowledging his contributions to pharmacy over more than four decades.

His career is defined by sustained excellence, innovation, and mentorship, and his legacy continues to shape the future of pharmacy in Australia and beyond.

"The PSA Excellence Awards acknowledge the pharmacists who go above and beyond, those who are involved in innovative practice, those who are striving to raise practice standards, and those whose professionalism provides a model of practice which others strive to emulate," Associate Professor Sim said. KB

Pictured: Anderson with Andrew Crawley, GM Pharmacy at Symbion, and Associate Professor Sim.

Arrotex and Celltrion partner on biosimilars

CELLTRION Healthcare
Australia and Australian-owned
Arrotex Pharmaceuticals
have entered into a strategic
agreement to launch two
new biosimilar medicines Steqeyma (ustekinumab) and
Omlyclo (omalizumab).

Both are listed on the Pharmaceutical Benefits Scheme (PBS) and available in pharmacies from today, and are the first PBS-listed biosimilars in their respective categories.

Steqeyma is indicated for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis, while Omlyclo is listed for uncontrolled severe asthma/allergic asthma, and severe chronic spontaneous urticaria.

As the sponsor of the medicines, Celltrion will be responsible for engaging with key prescribing physicians, while Arrotex will be the brand's exclusive distribution partner in Australia, covering community



pharmacy distribution as well as representation across the dermatology segment.

Arrotex Chief Commercial Officer Hayley Tamborini (pictured) said: "Our new alliance with Celltrion is complementary and important for many reasons."

"We are proud that Arrotex's strong market presence in community pharmacy and extensive distribution networks can truly be a game-changer in delivering Celltrion's biosimilars to the patients who need them most," she continued.

"Arrotex continues to focus on exclusive and first-to-market launches to bring increased value to community pharmacy," Tamborini concluded.



1800 429 829 info@ravensrecruitment.com.au

www.ravensrecruitment.com.au

Pharmacist in Charge.
Townsville, QLD. (Job #47966)

- Hourly rates \$60 up to \$100 on Public Hols.
- Strong support: multiple Pharmacists & Techs.
- Coastal lifestyle with city convenience.

This community Pharmacy is part of an established group located in a vibrant hub in coastal North Queensland.

...see more info



Friday 1st Aug 2025

Get your own copy of **Pharmacy Daily**

CLICK FOR YOUR FREE SUBSCRIPTION





Dispensary Corner

A MOTHER-OF-TWO from Wales has credited a pharmacist for saving her life.

The patient, known as Florrie, visited Shackleton's Pharmacy in Abergavenny to seek treatment for her throat infection.

She spoke to pharmacist Kyle Price, who assessed her before prescribing antibiotics, as well as handing her a leaflet and symptom card with information about the signs of sepsis - part of an awareness campaign run by the Aneurin Bevan University Health Board.

That proved vital the next day, when Florrie's condition dramatically worsened.

Realising she may have sepsis, she contacted emergency services and was diagnosed and successfully treated in hospital.

"I want to acknowledge everything that Kyle did that ultimately saved my two young children from losing their mummy," Florrie said.

"I cannot express my gratitude enough for everything he did, when I'm sure he was ready to shut up the pharmacy for the day at 4.55pm on a Fri evening.

"Sepsis itself is so scary, and without knowing about pharmacy services and utilising Kyle's experience, by the time I got home and saw my own registered GP on the Mon, it could have been too late."

Price said his intervention highlighted the potentially life-saving role that community pharmacists play:"I'm just glad I had the resources to hand... campaigns like this really do make a difference."

AD drug evidence bolstered

LONG-TERM efficacy data for the anti-amyloid therapy Kisunla (donanemab, Eli Lilly) was presented yesterday at the Alzheimer's Association International Conference in Toronto, Canada.

Kisunla is a disease-modifying therapy for Alzheimer's disease (AD) that helps immune cells clear amyloid plaques to slow cognitive and functional decline and maintain the ability to carry out everyday tasks.

The recent results demonstrated that the positive impact of Kisunla on cognition and daily function not only continues but increases well beyond the initial period of treatment, with a doubling of clinical benefit from 18 months to 36 months.

It also showed that the sooner Kisunla is initiated, the better the outcome for patients with early symptomatic AD.

Giving patients the drug earlier resulted in a 27% reduction in the risk of progression to the next stage of AD compared to those who received it 18 months later.

The medicine was recently registered on the Australian Register of Therapeutic Goods (PD 22 May), becoming the first new treatment registered in Australia for early Alzheimer's disease in 25 years, and the first treatment registered in Australia to address the underlying cause of the neurodegenerative disease.

An application to include Kisunla on the Pharmaceutical Benefits Scheme (PBS) was reviewed by the Pharmaceutical Benefits Advisory Committee (PBAC) in Jul, with the funding decision to be made public

The sponsor Eli Lilly said that until Kisunla is listed on the PBS, it will



be available on private prescription.

Federal Minister for Health, Mark Butler - who ultimately signs off on PBAC decisions - said on ABC's 7:30 on Mon, that the drug "is really exciting in the dementia space, a space that has not seen any really successful drug innovations in the 40 years since we first discovered the role of the amyloid protein on the brain in driving Alzheimer's".

Eli Lilly said it continues to work with the Australian Govt and Alzheimer's community to support the early detection, diagnosis and treatment of Alzheimer's disease. KB

New meds on PBS

SANDOZ has announced that its two new biosimiliar brands of denosumab, which is used to treat osteoporosis, are now listed on the Pharmaceutical Benefits Scheme (PBS).

More than 600,000 patients will now pay less to access Jubbonti 60mg/1ml solution for a prefilled syringe and Wyost 120mg/1.7ml solution for injection, which are the first new biosimiliar brands of denosumab available for public funding.

The PBS listing also creates new opportunities for community pharmacies, who can now administer denosumab injections in-pharmacy.

"The PBS listing of Jubbonti and Wyost marks a pivotal moment for healthcare sustainability in Australia," said Sandoz ANZ Head of Marketing, Natalie Armstrong.

WE'RE HIRING **Business Development Manager** Are you a driven sales professional looking for a new challenge? Join the Business Publishing Group, home to market-leading B2B titles including Travel Daily, Cruise Weekly and Pharmacy Daily. We're on the lookout for a Business Development Manager who For more information and to apply CLICK HERE. Travel Daily travelBulletin 🕏 CRUISE BUSINESS

Pharmacy

www.pharmacydaily.com.au

Pharmacy Daily is part of the **Business Publishing Group family** of publications.

Pharmacv Dailv is Australia's favourite pharmacy industry

EDITORIAL

Editor - Karina Brav Deputy Editor - Matt Lennon Journalists - Adam Bishop, Myles Stedman, Janie Medbury Editor-at-large - Bruce Piper

Associate Publisher - Jo-Anne Hui-Miller Editorial Director - Damian Francis

ADVERTISING AND MARKETING Head of Sales & Marketing Sean Harrigan

advertising@pharmacydaily.com.au

GENERAL MANAGER & PUBLISHER Matthew Vince

ACCOUNTS

accounts@traveldaily.com.au

Suite 1, Level 2, 64 Talavera Rd Macquarie Park NSW 2113 Australia Tel: 1300 799 220 (+61 2 8007 6760)

info@pharmacydaily.com.au



Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Damian Francis.



TO ATTRACT MORE CUSTOMERS, JUST USE THE RIGHT BAIT.

Everyday Glucojel buying deal, get 2.5% discount!*

*See your order portal for details.





AVAILABLE NOW (While stocks last!)



TRIMACORTE

Clotrimazole and Hydrcortisone Cream 15g & 30g

BROAD SPECTRUM

ANTI-FUNGAL

ANTI-INFLAMMATORY



Also available

Demacorte (30g)
Hydrocortisone
acetate 1% w/w

GET YOUR SPECIAL PHARMACY DEAL NOW!

orders@novapharm.com.au



T290725aS3vI.0 Ask your pharmacist about this product. Always read the label and follow the directions tor use. Read the warnings before purchase.